Latest Insider Transactions at Kiromic Biopharma, Inc. (KRBP)
This section provides a real-time view of insider transactions for Kiromic Biopharma, Inc. (KRBP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kiromic Biopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kiromic Biopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 26
2024
|
Pietro Bersani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
988
+0.69%
|
$988
$1.93 P/Share
|
|
Aug 23
2024
|
Pietro Bersani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.74%
|
$5,000
$2.2 P/Share
|
|
Aug 20
2024
|
Brian Hungerford Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,742
+5.45%
|
$7,484
$2.2 P/Share
|
|
Aug 19
2024
|
Brian Hungerford Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
258
+0.42%
|
$516
$2.25 P/Share
|
|
Aug 13
2024
|
Brian Hungerford Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+3.18%
|
$2,000
$1.75 P/Share
|
|
Jun 13
2024
|
Brian Hungerford Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.67%
|
$2,000
$2.6 P/Share
|
|
Jun 12
2024
|
Pamela Misajon Director |
BUY
Open market or private purchase
|
Direct |
1,610
+2.73%
|
$4,830
$3.27 P/Share
|
|
Jun 12
2024
|
Pietro Bersani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+2.12%
|
$9,000
$3.28 P/Share
|
|
Jun 12
2024
|
Brian Hungerford Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.7%
|
$3,000
$3.18 P/Share
|
|
Jun 11
2024
|
Pietro Bersani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+2.16%
|
$9,000
$3.23 P/Share
|
|
Jun 11
2024
|
Michael Nagel Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.26%
|
$3,000
$3.33 P/Share
|
|
Jun 10
2024
|
Pamela Misajon Director |
BUY
Open market or private purchase
|
Direct |
1,701
+5.89%
|
$3,402
$2.93 P/Share
|
|
May 03
2024
|
Brian Hungerford Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,933
+38.89%
|
-
|
|
May 03
2024
|
Pietro Bersani Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,968
+50.0%
|
-
|
|
Mar 18
2024
|
Michael Nagel Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+29.85%
|
-
|
|
Mar 18
2024
|
Pamela Misajon Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+41.38%
|
-
|
|
Mar 18
2024
|
Michael Catlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+41.38%
|
-
|
|
Aug 11
2022
|
Scott Dahlbeck Chief of Staff |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+9.14%
|
-
|
|
Aug 11
2022
|
Daniel Grant Clark Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+44.34%
|
-
|
|
Aug 11
2022
|
Pietro Bersani Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
638,298
+50.0%
|
-
|
|
May 23
2022
|
Scott Dahlbeck Chief of Staff |
BUY
Exercise of conversion of derivative security
|
Direct |
17,240
+3.72%
|
-
|
|
Sep 09
2021
|
Internati Maurizio Chiriva CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
2,800
+0.2%
|
$8,400
$3.7 P/Share
|
|
Jul 13
2021
|
Michael Charles Ryan Officer |
BUY
Other acquisition or disposition
|
Direct |
50,189
+50.0%
|
-
|
|
May 24
2021
|
Jerry A. Schneider Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$35,000
$7.31 P/Share
|